

Reference:	FOI.10470.22
Subject:	Treatment for Haematology patients
Date of Request:	8 December 2022

Requested:

Could you please provide the number of patients treated (for any disease in the past 3 months with:

- Aragam
- Berinert
- Cinryze
- Cutaquig
- Cuvitru
- Firazyr
- Flebogamma DIF
- Gammagard
- Gammanorm
- Gammaplex
- Gamunex
- Hizentra
- Hyqvia
- Intratect
- Iqymune
- Kiovig
- Octagam
- Orladeyo
- Panzyga
- Privigen
- Ruconest
- Subgam
- Takhzyro

Response:

The table provides the number of patients treated with the named medications by Hywel Dda University Health Board (UHB) between 1 September and 30 November 2022.

Drug	Number
Aragam	0
Berinert (c1 esterase inhibitor)	0
Cinryze (c1 esterase inhibitor)	0
Cutaquig	0
Cuvitru	0
Firazyr	0
Flebogamma DIF	9
Gammagard	0
Gammanorm	0

Gammaplex	0
Gamunex	*
Hizentra	0
Hyqvia	0
Intratect	*
Iqymune	*
Kiovig	*
Octagam	*
Orladeyo (berotralstat)	0
Panzyga	0
Privigen	28
Ruconest (conestat alfa)	0
Subgam	*
Takhzyro (lanadelumab)	0

* Where the figures in the table have been replaced with an asterisk, the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act (DPA) 2018 / General Data Protection Regulations (GDPR) 2016, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018 / General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.